Schefke D M, Fontana D J, Commissaris R L
Department of Pharmaceutical Sciences, College of Pharmacy, Wayne State University, Detroit, MI 48202.
Psychopharmacology (Berl). 1989;99(3):427-9. doi: 10.1007/BF00445572.
In many animal studies, acute treatment with the novel anxiolytic agent buspirone exhibits only minimal "anxiolytic efficacy" (i.e., increases in punished responding) when compared to benzodiazepines and barbiturates. The present studies examined the effects of acute pre-test challenges with buspirone in subjects receiving chronic post-test buspirone or saline treatments. Chronic post-test treatment with buspirone (4 mg/kg/day for 4 weeks, followed by 8 mg/kg/day for 12 weeks) did not significantly affect CSD behavior. Consistent with previous reports, acute pre-test administration of buspirone (0.125-2 mg/kg, IP) to subjects receiving chronic post-test saline treatment resulted in only a modest anti-conflict effect in the CSD paradigm (approximately ten shocks over control). In contrast, subjects chronically treated with buspirone exhibited a dramatically greater anti-conflict effect following acute challenge with buspirone (up to 40 shocks over control). These data are consistent with the hypothesis that the full anxiolytic efficacy of buspirone requires repeated administration.
在许多动物研究中，与苯二氮䓬类药物和巴比妥类药物相比，新型抗焦虑药物丁螺环酮的急性治疗仅表现出极小的“抗焦虑功效”（即，惩罚反应增加）。本研究考察了在接受慢性测试后丁螺环酮或生理盐水治疗的受试者中，急性测试前给予丁螺环酮的效果。丁螺环酮的慢性测试后治疗（4毫克/千克/天，持续4周，随后8毫克/千克/天，持续12周）对冲突性逃避行为没有显著影响。与之前的报告一致，对接受慢性测试后生理盐水治疗的受试者急性测试前给予丁螺环酮（0.125 - 2毫克/千克，腹腔注射），在冲突性逃避范式中仅产生适度的抗冲突效应（比对照组多约10次电击）。相比之下，长期接受丁螺环酮治疗的受试者在急性给予丁螺环酮挑战后表现出显著更强的抗冲突效应（比对照组多多达40次电击）。这些数据与丁螺环酮的完全抗焦虑功效需要重复给药的假设一致。
